BIC LEN HIV Treatment: New Single-Tablet Regime...

By João L. Carapinha

February 26, 2026

BIC/LEN HIV Treatment Maintains Suppression in Switch Studies Phase 3 results from Gilead Sciences' ARTISTRY-1 and ARTISTRY-2 trials, presented at the 2026 Conference on R...
NICE Approves Ruxolitinib Cream for Treating Vitiligo with Facial Involvement
Economic Impact of Industry Clinical Trials in Europe
EMA Validation of ENHERTU Breast Cancer Treatment for Post-Neoadjuvant Therapy
European Commission Approves Enhanced Wegovy Obesity Treatment Dose
Genotype ECG Prediction
NICE Endorses Pegzilarginase for Treating Arginase Deficiency
Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion i...
KEYTRUDA Ovarian Cancer Treatments: FDA Approves New Regimens for Platinum-Re...
National HealthTech Access: Transforming NHS Adoption and Equity
Datroway Metastatic Breast Cancer: FDA Grants Priority Review for Breakthroug...
FDA Confirms GLP-1 RA Safety Review: No Increased Suicidal Risk